Special Editorial Review
Endocannabinoids in arthritis: current views and perspective
Abstract
Preclinical and clinical studies using cannabis‐based therapy have been shown to provide both analgesia and anti‐inflammatory effects, with an overall alleviation of clinical symptoms in animal models of arthritis, highlighting its promising therapeutic application for humans. Despite this, the development of cannabis‐based therapeutics remains in its infancy, with further investigation into its efficacy and safety profile in patients still required. This synopsis reviews the various components of the endocannabinoid system in health and disease and their potential as therapeutic targets.
Citing Literature
Number of times cited according to CrossRef: 5
- Robert P. Runner, Andrew N. Luu, Nader A. Nassif, Travis S. Scudday, Jay J. Patel, Steven L. Barnett, Robert S. Gorab, Use of Tetrahydrocannabinol and Cannabidiol Products in the Perioperative Period Around Primary Unilateral Total Hip and Knee Arthroplasty, The Journal of Arthroplasty, 10.1016/j.arth.2020.01.077, (2020).
- Luke Daniel Williamson, Peter Wong, Nicholas Manolios, The ha(r)sh‐drug interactions in rheumatology, International Journal of Rheumatic Diseases, 10.1111/1756-185X.13939, 23, 9, (1258-1260), (2020).
- Daphna Katz-Talmor, Itay Katz, Bat-Sheva Porat-Katz, Yehuda Shoenfeld, Cannabinoids for the treatment of rheumatic diseases — where do we stand?, Nature Reviews Rheumatology, 10.1038/s41584-018-0025-5, 14, 8, (488-498), (2018).
- Morouj Ismail, Ghada Khawaja, Study of cannabinoid receptor 2 Q63R gene polymorphism in Lebanese patients with rheumatoid arthritis, Clinical Rheumatology, 10.1007/s10067-018-4217-9, 37, 11, (2933-2938), (2018).
- Silvia L. Cruz, Elizabeth Sánchez-Miranda, Jorge Ivan Castillo-Arellano, Rodolfo Daniel Cervantes-Villagrana, Alfredo Ibarra-Sánchez, Claudia González-Espinosa, Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB2 and GPR55 receptor activation. Possible involvement of CB2-GPR55 heteromers, International Immunopharmacology, 10.1016/j.intimp.2018.09.006, 64, (298-307), (2018).
